Kyverna Therapeutics (NASDAQ:KYTX) Posts Earnings Results

Kyverna Therapeutics (NASDAQ:KYTX) released its earnings results on Thursday. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.01, FiscalAI reports.

Kyverna Therapeutics Stock Down 2.0%

KYTX stock traded down $0.10 during trading on Friday, hitting $4.93. 424,148 shares of the company’s stock were exchanged, compared to its average volume of 910,032. The business has a 50-day moving average price of $6.28 and a two-hundred day moving average price of $7.90. The company has a current ratio of 9.06, a quick ratio of 9.06 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $304.81 million, a price-to-earnings ratio of -1.67 and a beta of 2.12. Kyverna Therapeutics has a 52-week low of $4.49 and a 52-week high of $13.67.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on KYTX shares. HC Wainwright reaffirmed a “buy” rating on shares of Kyverna Therapeutics in a report on Thursday, October 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, September 21st. William Blair upgraded Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Benchmark reiterated a “buy” rating on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Finally, Needham & Company LLC set a $25.00 target price on Kyverna Therapeutics in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.